2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bone Marrow Failure Syndromes, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4724 Inducing surface calreticulin in tumor associated macrophages restores phagocytic tumor clearance

Hargunpreet Singh Kharoud, N/A, Allison Banuelos, PhD2, Irving Weissman, MD3
1 Stanford School of Medicine, Stanford, California, United States
2 Stanford School of Medicine, Stanford, California, United States
3 Stanford School of Medicine, Stanford, California, United States
Background: Tumor-associated macrophages (TAMs) are key effectors of CD47 checkpoint blockade, yet their capacity to engulf tumor cells varies dramatically. Although TAM polarization (M1/M2) is commonly used to predict antitumor activity, macrophages within identical polarization states display striking heterogeneity in tumor engulfment. We sought to define the molecular drivers of this "Eater" phenotype and evaluate whether therapeutic CALR induction in TAMs can restore anti-tumor phagocytosis.
Methods: Primary human macrophages were co-cultured with tumor cells and prospectively sorted into "Eater" and "Non-Eater" TAM subsets based on tumor uptake. Bulk RNA sequencing, high-dimensional surface phenotyping, functional antibody blockade, TLR4 activation with monophosphoryl lipid A (MPLA), recombinant calreticulin (CALR), and in vivo DLD-1 xenograft models were used to interrogate and therapeutically target this pro-phagocytic state.
Results: Eater TAMs exhibited a distinct transcriptional program enriched in Unfolded Protein Response (UPR) and Integrated Stress Response (ISR) pathways. While M1 macrophages showed higher baseline phagocytosis than M2 macrophages, marked functional heterogeneity persisted within every polarization state, demonstrating that conventional M1/M2 status fails to dictate phagocytic capacity. Surface profiling identified calreticulin (CALR) as a defining hallmark of Eater TAMs. Despite reduced CALR transcript abundance, Eater TAMs displayed a 1.5-fold increase in surface CALR protein, reflecting stress-induced post-translational translocation. CALR high TAMs exhibited 1.5-fold greater tumor cell engulfment than CALR low TAMs, whereas CALR blockade significantly impaired phagocytosis. TLR4 activation via MPLA induced surface CALR on TAMs and boosted tumor clearance. In vivo, combining MPLA with anti-CD47 resulted in reduced tumor growth compared to either monotherapy. Furthermore, direct intratumoral administration of recombinant CALR alone was sufficient to induce TAM-mediated tumor suppression.
Conclusions: We identify a stress-associated, surface CALR-dependent TAM state that predicts tumor phagocytic capacity far more accurately than conventional M1/M2 polarization. Therapeutic CALR induction in TAMs via TLR4 activation or local delivery overrides phagocytic resistance, providing a powerful strategy to potentiate CD47-targeted cancer immunotherapies.
Hargunpreet Singh Kharoud, N/A: No relevant conflicts of interest to declare.